Making patient-derived tumor organoids a reliable cancer therapy testing platform

We aim to establish a European network of experts in non-animal preclinical models to develop the next generation of patient-derived tumor organoids (PDTOs) for both solid and hematological cancers. To this end, we have selected non-small cell lung cancer as a model, given its high incidence, and chronic lymphocytic leukemia and follicular lymphoma as representative B cell malignancies.These PDTOs will incorporate a novel, tissue-specific artificial extracellular matrix, created using tailored 3D biohybrid hydrogels designed to mimic the human tumor microenvironment (TME). By integrating patient-derived tumor, immune, and stromal cells, the PDTOs will closely replicate the complexity of the original tumors, which will be evaluated using a multi-technique approach, including comprehensive omics characterization.Our ultimate goal is to establish a robust platform for testing innovative therapies—particularly radiotherapy and immunotherapy—within the framework of personalized medicine. Specifically, we will focus on adoptive cell therapies using CAR T and NK cells, neutron capture (radio)therapy, and their combination.